secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2026-08-24T10:01:23+00:00
Accession:  0001193125-26-361705
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek jury verdict: noninfringement on 3 of 4 patent claims, $56.11M damages on 1 claim; appeal planned
--------------------------------------------------------------------------------

- Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).
- One claim infringed under doctrine of equivalents; damages: $20M lost profits + $36.11M royalties.
- Cytek will pursue post-verdict motions and potential appeal to Federal Circuit.
- Verdict requires no changes to current products; spectral flow cytometry remains available globally.
- CEO Wenbin Jiang says Cytek developed fundamentally different Full Spectrum Profiling technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/0001193125-26-361705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/d137695d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-361705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer